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 Previous reports of multiple sclerosis (MS) with autoantibodies might include 
neuromyelitis optica (NMO). We investigated the frequency of autoreactive antibodies 
(AR) in both MS and NMO. Systemic lupus erythematosus (SLE)-associated 
autoantibodies such as anti-Sm antibodies, anti-single stranded-DNA antibodies and 
lupus anticoagulant were only identified in MS, whereas SLE itself is more commonly 
associated with NMO. Moreover, when magnetic resonance imaging features between 
autoreactive antibody-positive (AR(+))MS and -negative (AR(-))MS were compared, 
AR(+)MS cases showed significantly fewer than 3 periventricular lesions compared to 
AR(-)MS cases. These results may indicate different pathogenetic mechanisms 
underlying AR(+)MS and AR(-)MS.  
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1. Introduction 
 Multiple sclerosis (MS) is considered a Th1-mediated autoimmune disease of the 
central nervous system (CNS) and is characterized by phases of remission and relapse 
(Martin et al., 1992; Hafler and Weiner, 1995).  To date, no specific biomarker for MS 
has been identified, which may indicate the heterogeneous pathogenesis of MS. 
Subpopulations of MS are often discussed from clinical or immunological perspectives 
(Takahashi et al., 2001; Weinshenker et al., 2005; Satoh et al., 2006). The relationship of 
MS to other autoimmune diseases has also been discussed; that is, autoantibodies 
common in other autoimmune diseases can also be found in patients with MS. For 
example, anti-nuclear antibodies (ANA) are detected in 20 to 26% of MS cases (Collard 
et al., 1997; Tourbah et al., 1998; de Andres et al., 2001; De Keyser, 1988), anti-SS-A 
antibodies in 2 to 7% of MS cases (Tourbah et al., 1998; de Andres et al., 2001) and 
anti-cardiolipin antibodies in 2% of MS cases (de Andres et al., 2001). 
   In contrast, the opticospinal form of MS (OSMS) has been characterized in Japan 
and other Asian countries (Nakashima et al., 2006; Kira, 2003). Since both OSMS and 
neuromyelitis optica (NMO) characteristically involve the optic nerves and the spinal 
cord, the differences between these diseases has been discussed especially in Japan 
(Matsuoka et al., 2008). The development of magnetic resonance imaging (MRI) 
technology and the discovery of anti-aquaporin-4 (AQP4) antibodies have resulted in 
the revision of diagnostic criteria for NMO in 2006 (Wingerchuk et al., 2006). Recently, 
some groups have reported that the OSMS in Japan is consistent with NMO in that the 
AQP4 antibody can be identified in both populations (Nakashima et al., 2006; Lennon 
et al., 2004). Moreover, NMO is more commonly associated with other systemic 
autoimmune diseases, such as SLE or Sjögren syndrome (SjS), compared to typical MS 
(Pittock et al., 2008). These associations indicate that NMO patients may be included in 
previous reports regarding the identification of autoreactive antibodies in MS.  
  The purpose of this study was to investigate the frequency with which autoreactive 
antibodies can be identified in both MS and NMO followed by comparisons of the 
clinical and magnetic resonance imaging (MRI) features found in both autoreactive 




 Enrollment for this study began in January 2010 and was completed in December 2011. 
Written informed consent was obtained from all patients, and the study was approved by 
the Ethics Committee of the Iou Hospital and Kanazawa University. Inclusion criteria 
for subjects with MS included: (1) 2 or more attacks and objective clinical evidence of 2 
or more lesions; (2) brain and spinal cord MRI; (3) complete analysis of a broad panel 
of autoreactive antibodies (ANA, anti-AQP4, anti-double stranded DNA antibodies 
(dsDNA), anti-single stranded DNA antibodies (ssDNA), anti-ribonucleoprotein 
antibodies (RNP), anti-SS-A/Ro antibodies (SS-A), anti-SS-B/La antibodies (SS-B), 
anti-Sm antibodies (Sm), PR3-anti-neutrophil cytoplasmic antibodies (ANCA), 
MPO-ANCA, anti-cardiolipin antibodies (aCL), anti-cardiolipin-beta-2 glycoprotein I 
antibodies (aCLb2GPI), anti-topoisomerase I antibodies (Scl-70), anti-thyroid 
peroxidase antibodies (aTPO), anti-thyrogloblin antibodies (aTG), lupus anticoagulant 
(LAC), and rheumatoid factor (RF)). NMO, defined by the revised NMO criteria by 
Wingerchuk in 2006, was also included when all inclusion criteria were fulfilled. 
Exclusion criteria included: (1) primary or secondary progressive MS; (2) clinically 
isolated syndrome (CIS); and (3) immunosuppressive treatment within the last 6 months 
prior to blood sampling. 
 
2.2 Autoreactive antibodies 
 Autoreactive antibodies were measured using a commercially available laboratory 
assay.  The majority of testing was performed at the clinical laboratory of Kanazawa 
University.  The fluorescence antibody method (FA) was used for measurement of 
ANA and anti-AQP4. Enzyme-linked immunosorbent assay (ELISA) was used for 
measurement of dsDNA, ssDNA, RNP, Sm, SS-A, SS-B, PR3- ANCA, MPO-ANCA, 
aCL, aCLb2GPI, and Scl-70, and chemiluminescence enzyme immunoassay (CLEIA) 
was used for measurement of aTPO and aTG. LAC was measured using the dilute 
Russell’s viper venom time (dRVVT) assay and kaolin clotting time (KCT) assay. RF 
was measured by nephelometry. High positive cut-off values for ANA (1:160 serum 
dilution) and RF (15 IU/ml) were used to exclude 95% of normal individuals (Tan et al., 
1997). Normal range for dsDNA, ssDNA, RNP, Sm, SS-A, SS-B, PR3- ANCA, 
MPO-ANCA, aCL, aCLb2GPI, and Scl-70, aTPO, aTG and LAC were also set to 
exclude at least 95% of normal individuals. To exclude temporary positivity, 
auto-reactive antibodies were defined as “positive” when detected at least twice in tests 
performed at least 12 weeks apart, with the exception of aAQP4. aAQP4 was 
considered “positive” with at least 1 positive result. 
 
2.3 Cerebrospinal fluid collection 
Cerebrospinal fluid (CSF) was collected from patients in relapse, prior to treatment with 
methylprednisolone. Myelin basic protein (MBP) was measured using 
radioimmunoassay (RIA). The oligoclonal band (OB) was measured by isoelectric 
focusing electrophoresis as previously reported. In brief, both CSF and serum samples 
were diluted with phosphate-buffered saline (PBS). Diluted CSF and serum samples 
were applied to isoelectric focusing (IEF) gel and prefocused. After the IEF run, specific 
IgG bands were precipitated in gel by immunofixation and the immunoprecipitate was 
silver-stained. An OB was defined as 2 or more distinct bands in the CSF sample, but 
not visible in the paired serum sample. MBP and OB were each considered “positive” 
with at least 1 positive result. 
 
2.4 MRI acquisition and examination 
A 1.5 or 3T MRI scanner was used to collect the following image sequences: (1) fluid 
attenuated inversion recovery (FLAIR); (2) T2-weighted spin echo; and (3) 
post-contrast T1-weighted spin echo. 
 
2.5 Statistical analysis 
Fisher’s exact test was used for comparison of MRI and CSF data and the 
Mann-Whitney U-test was used for comparison of values between the groups. Values of 
p < 0.05 were considered significant. All quantitative data are presented as mean (SD). 
Statistical calculations were performed using SPSS 18.0 software (IBM, Armonk, NY). 
 
3. Results 
3.1 Demographics of MS and NMO patients 
A total of 47 patients fulfilled the inclusion criteria for MS and 10 patients among them 
met the revised NMO criteria. Table 1 shows the clinical characteristics of the study 
population. Nine patients with NMO (90%) were aAQP4 positive and 8 of them (80%) 
showed the contiguous T2-weighted signal abnormality on spinal MRI extending 3 or 
more vertebral segments. The 37 patients with MS (female/male: 25/12) had disease 
onset at the age of 30.1 (11.3) years (range 3—60), mean disease duration of 9.9 (9.8) 
years (range 1—42) and a mean expanded disability status scale (EDSS) of 2.8 (2.8) 
(range 0—7.5). The 10 patients with NMO (female/male 8/2) had mean disease onset at 
the age of 42.3 (13.5) (range 22—65), mean disease duration of 12.5 (12.8) years (range 
3—45), and a mean EDSS of 4.7 (3.6) (range 1—9.5). Six of the patients with MS 
received beta-interferon therapy, while the other patients did not receive any 
disease-modifying therapy. 
 
3.2 Frequency and distribution of autoreactive antibodies 
The distribution of subtypes of autoreactive antibodies in patients with MS and NMO is 
shown in Table 2. Fifteen (41%) patients with MS and 7 (70%) patients with NMO were 
positive for 1 or more autoreactive antibodies. Although RF, SS-A, aTG, and aTPO 
were demonstrated in both groups, all of these autoreactive antibodies were detected 
with a higher frequency in NMO. In contrast, ANA, Sm, ssDNA and LAC were only 
positive in MS, while PR3-ANCA was only positive in NMO. When LAC was positive 
in patients with MS it was only demonstrated with the KCT assay, not the dRVVT assay. 
No patients in either group were positive for RNP, SS-B, aCL, aCLb2GPI, MPO-ANCA, 
Scl-70, or centromere antibodies. Finally, anti-mitochondrial antibodies (AMA) were 
positive in a single patient with MS and thyroid receptor-stimulating antibodies (TRs) 
were positive in 2 patients with NMO. 
 
3.3 Association with autoimmune diseases 
Overall, 9 (24.3%) patients with MS had an association with other autoimmune diseases 
(OAD). Hashimoto thyroiditis (4) was the most common. Psoriasis, ulcerative colitis 
(UC), anti-phospholipid syndrome (APS), primary biliary cirrhosis (PBC), and Sjögren 
syndrome (SjS) were each identified in a single patient. In patients with NMO, 6 of 10 
(60.0%) had associated OAD, most commonly SjS (2/10) and Graves’ disease (2/10). 
Systemic lupus erythematosus (SLE) and Hashimoto thyroiditis were each identified in 
a single patient. 
 
3.4 Clinical correlation between AR(+)MS and AR(-)MS 
The comparison of clinical features and CSF data between autoreactive antibody 
positive-(AR(+)) and negative-(AR(-)) patients with MS is shown in Table 3. No 
difference was found in age of onset, disease duration and EDSS. The 15 patients with 
AR(+)MS (female/male 10/5) had mean disease onset at the age of 32.5 (11.3) years 
(range 18—60), mean disease duration of 9.9 (10.5) years (range 1—42), and a mean 
EDSS of 2.7 (3.0) (range 0—7.5). The 22 patients with AR(-)MS (female/male 16/6) had 
mean disease onset at the age of 28.4 (11.4) years (range 22—65), mean disease duration 
of 12.5 (12.8) years (range 1—38), and a mean EDSS of 2.9 (2.6) (range 0—9). 
Cerebrospinal fluid analysis was performed in the 14 (93%) patients with AR(+)MS and 
the 17 (77%) patients with AR(-)MS. The frequency of OB and MBP was similar in the 
AR(+)MS and AR(-)MS groups.  
 
3.5 Correlation with MRI findings between AR(+)MS and AR(-)MS 
The comparison of MRI findings between patients with AR(+)MS and AR(-)MS is 
shown in Table 4. Five (33%) patients with AR(+)MS fulfilled the MRI criteria from the 
2005 revision of MS diagnostic criteria, which is a significantly low proportion 
compared to the AR(-)MS group (16 of 22; 73%) (p = 0.023). The number of patients 
with AR(+)MS with more than 3 periventricular lesions was significantly lower than the 
AR(-)MS group. In contrast, when the MRI criteria from the 2010 revision of MS 
diagnostic criteria were used, there was no difference between the AR(+)MS and 
AR(-)MS groups (p = 0.198).  
 
4. Discussion 
 The frequency of autoreactive antibodies found in the current study, except for aCL, 
was similar to those found in previous reports (Collard et al., 1997; Tourbah et al., 1998; 
de Andres et al., 2001; De Keyser, 1988; Takahashi, 2010). Although previous studies 
have reported an increased aCL titer in both MS and NMO (Fukazawa et al., 1993; Garg 
et al., 2007), no patients in either group showed “positive” aCL results in this study. 
This difference may be explained by aCL often showing temporary positivity, as 
described in the diagnostic criteria for APS (Miyakis et al., 2006). ANA and RF can be 
seen in a few healthy individuals, but a high positive cut-off value for ANA, 1:160 
serum dilution, would likely exclude 95% of normal individuals (Tan et al., 1997). 
Since 4 (11%) patients with MS were ANA-positive in this study, it is likely that a 
patient with MS can become ANA-positive more easily than a healthy individual. 
Surprisingly, no patient with NMO was ANA-positive, although we expected higher 
frequency of ANA in the patients with NMO than with MS. However, when we used a 
low positive cut-off value for ANA, 1:40 serum dilution (expecting 32% positive in 
healthy individuals), 9 (24%) patients with MS and 4 (40%) patients with NMO became 
positive for ANA. This frequency of ANA in NMO patients was similar to that in a 
previous report (Pittock et al., 2008). Moreover, in this study, the sample size of NMO 
group is too small to clarify the frequency of ANA in patients with NMO. Using a 
cut-off value of 15 IU/mL for RF should also exclude 95% of normal individuals and 
since 2 (5%) patients with MS were RF-positive in this study, it is likely that 
RF-positivity occurs in a patient with MS at a similar frequency to that in healthy 
individuals. 
 In agreement with the results of this study, MS associated with gastrointestinal 
autoimmune diseases, such as UC, Crohn’s disease, and PBC has been previously 
reported, but NMO has not been associated with these diseases (Pokorny et al., 2007; 
Pontecorvo et al., 1992; Cohen et al., 2008). In this study, SLE, the representative 
systemic autoimmune disease, was only shown in NMO. Although SjS and autoimmune 
thyroid diseases were shown in both MS and NMO, organ-specific autoimmune 
diseases seem to be somewhat related to MS and systemic autoimmune diseases seem 
somewhat related to NMO. Interestingly, SLE-associated autoantibodies such as Sm, 
ssDNA, and LAC were seen only in patients with MS in this study, whereas SLE itself 
has a higher incidence in NMO than in MS. It is well known that type 1 interferon 
would promote not only the production of autoantibodies but also induction of 
drug-induced SLE (Neau et al., 1996; Crispín et al., 2005; Bronaci-Nikolic B et al., 
2009; Sladkova V et al., 2011). In our study, although 6 of 37 patients with MS received 
beta-interferon therapy, only a single patient was ssDNA positive without positivity of 
any other autoreactive antibodies. These data indicate that SLE-associated 
autoantibodies such as Sm, ssDNA, and LAC in the patients with MS are independent 
of beta-interferon therapy. Among autoantibodies related to APS, aCL has been reported 
mainly in relation to NMO, not MS (Fukazawa et al., 1993; Takahashi, 2010b). The 
relationship between LAC in MS and aCL in NMO remains unknown. Sm, ssDNA, and 
LAC may be associated with CNS involvement but not SLE itself. 
 None of the patients in either the MS or NMO group had RNP, MPO-ANCA, Scl-70, 
or centromere antibodies. These results are supported by the fact that previous studies 
rarely report an association of MS with mixed connective tissue disease (MCTD), 
vasculitis, or systemic sclerosis (SSc) specifically associated with these autoreactive 
antibodies (Takahashi, 2010a). 
 In Asia, including in Japan, NMO is more commonly diagnosed than that in western 
countries. Moreover, the opticospinal form of MS is more common than typical MS. 
NMO and MS along with other collagen diseases, are considered contraindications for 
interferon therapy. Immune modulating therapy must also be chosen carefully in 
patients with MS with autoreactive antibodies, especially SLE-associated autoantibodies 
(Sm, aCL, and LAC).  
 In this study, the MRI criteria from the 2005 revised MS diagnostic criteria was used 
to distinguish typical MS from NMO or MS with autoreactive antibodies. Interestingly, 
the number of patients with AR(+)MS with more than 3 periventricular lesions was 
significantly lower than in the AR(-)MS group. The periventricular plaque forms a 
lesion around a subependymal vein in the early stage (Adams et al., 1987). Autoimmune 
cells of AR(+)MS may be different form those of AR(-)MS, with respect to their affinity 
for the epithelium cells of the subependymal vein; this may indicate heterogeneity of 
pathogenesis of MS. Moreover, the MRI criteria from the 2010-revised McDonald 
criteria for MS was unable to detect a distinction and included all patients with NMO 
and 80% of patients with MS with autoreactive antibodies. Specifically, a diagnosis of 
MS included 27% of the AR(+)MS group by the 2005-revised MRI criteria and 73% by 
the 2010-revised MRI criteria. These results indicate that the presence of autoreactive 
antibodies, including aAQP4, should be carefully monitored, especially in Japan.  
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Table 1. Demographic characteristics 
 
MS NMO 
No. of patients 37 10 
Sex (female/male) 25/12 8/2 
Age, years (SD) 40.3 (12.2) 51.0 (13.3) 
Age at onset, years (SD) 30.1 (11.3) 42.3 (13.5) 
Disease duration, years (SD) 9.9 (9.8) 12.5 (12.8) 
EDSS, mean (SD) 2.8 (2.8) 4.7 (3.6) 
DMT 6 0 
 




Table 2. Frequency (%) and distribution of autoreactive antibodies in MS and NMO 
 
Autoreactive antibodies MS (n = 37) NMO (n = 10) 
Positive autoreactive antibodies 15(41%) 7(70%) 
ANA 4(11%) 0(0%) 
RF 2(5%) 2(20%) 
RNP 0(0%) 0(0%) 
SS-A 1(3%) 2(20%) 
SS-B 0(0%) 0(0%) 
Sm 1(3%) 0(0%) 
ssDNA 2(5%) 0(0%) 
dsDNA 0(0%) 0(0%) 
aCL 0(0%) 0(0%) 
aCLb2GPI 0(0%) 0(0%) 
LAC 5(14%) 0(0%) 
PR3-ANCA 0(0%) 1(10%) 
MPO-ANCA 0(0%) 0(0%) 
aTG 6(16%) 3(30%) 
aTPO 6(16%) 3(30%) 
Scl-70 0(0%) 0(0%) 
Centromere 0(0%) 0(0%) 
others AMA 1(3%) TRs 2(20%) 
 
ANA, antinuclear antibodies; RF, Rheumatoid factor; RNP, anti-ribonucleoprotein 
antibodies; SS-A, anti-SS-A/Ro antibodies; anti-SS-B/La antibodies (SS-B), Sm, 
anti-Sm antibodies; ssDNA, anti-single stranded DNA antibodies; dsDNA, anti-double 
stranded DNA antibodies; aCL, anticardiolipin antibodies; aCLb2GPI, 
anticardiolipin-beta-2 glycoprotein I antibodies; LAC, lupus anticoagulant; PR3-ANCA, 
PR3-anti-neutrophil cytoplasmic antibodies; MPO-ANCA, MPO-anti-neutrophil 
cytoplasmic antibodies; aTPO, anti-thyroid peroxidase antibodies; aTG, 
anti-thyrogloblin antibodies; Scl-70, anti-topoisomerase I antibodies; Centromere, 
anti-centromere antibodies; AMA, anti-mitochondrial antibodies; TRs, anti-thyroid 
receptor stimulating antibodies. 
Table 3. Comparison of clinical features and CSF markers between AR(+)MS and 
AR(-)MS 
 
AR(+)MS AR(-)MS †p -value 
No. of patients 15 22 
Sex (female/male) 10/5 16/6 
Age, years (SD) 42.4 (14.1) 38.8 (10.8) 0.545 
Age at onset, years (SD) 32.5 (11.3) 28.4 (11.4) 0.377 
Disease duration, years (SD) 9.9 (10.5) 10.0 (9.6) 0.791 
EDSS, mean (SD) 2.7 (3.0) 2.9 (2.6) 0.531 
DMT 1 5 
OB 6/14 (43%) 5/17 (29%) 0.477 
MBP 5/14 (36%) 4/17 (29%) 0.693 
 
CSF, cerebrospinal fluid; AR(+)MMS, autoreactive antibodies-positive MS; AR(-)MS, 
autoreactive antibodies-negative MS; EDSS, Expanded Disability Status Scale; DMT, 
disease modifying therapy (beta-interferon); OB, oligoclonal band; MBP, myelin basic 
protein; †p-value represent a comparison between AR(+)MS and AR(-)MS using the 
Mann-Whitney U test or the Fisher's exact test.  Values in bold are significant (p < 
0.05) 
  
Table 4. Comparison of MRI features between AR(+)MS and AR(-)MS 
 
AR(+)MS AR(-)MS †p-value 
McDonald 2005 5/15 (33%) 16/22 (73%) 0.023 
>9 T2 or >1 enhanced lesion 6/15 (40%) 14/22 (64%) 0.193 
>1 infratentorial lesion 11/15 (73%) 15/22 (68%) 0.516 
>1 juxtacortical lesion 8/15 (53%) 18/22 (82%) 0.08 
>3 periventricular lesion 6/15 (40%) 17/22 (77%) 0.038 
McDonald 2010 11/15 (73%) 20/22 (91%) 0.198 
 
†p-value represents a comparison between AR(+)MS and AR(-)MS using the Fisher's 
exact test. Values in bold are significant (p < 0.05) 
